title: Coagulation profiles and thromboembolic events of bortezomib plus thalidomide and dexamethasone therapy in newly diagnosed multiple myeloma.
abstract: Patients with multiple myeloma (MM) are at relatively high risk of developing thromboembolic event (TEE), especially during treatment with immunomodulatory agents. We characterized coagulation profiles and evaluate the incidence of TEE associated with the combination therapy of bortezomib-thalidomide-dexamethasone (VTD) in Chinese patients with newly diagnosed MM. The results indicated that the platelet count and platelet aggregation induced by the agonists were decreased after a short exposure to bortezomib in vivo. The incidence of TEE was low in VTD therapy for an overall rate of 3%. We do not recommend routine thromboprophylaxis for VTD therapy in Chinese patients with MM.
authors.affiliation: Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, 299 Qingyang Road, Wuxi 214023, China.
authors.forename: Yunfeng
authors.initials: Y
authors.lastname: Shen
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.forename: Zhi
authors.initials: Z
authors.lastname: Wang
authors.forename: Guohua
authors.initials: G
authors.lastname: Yang
authors.forename: Yuanqiang
authors.initials: Y
authors.lastname: Jiang
authors.forename: Chao
authors.initials: C
authors.lastname: Sun
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Tong
authors.forename: Hongfeng
authors.initials: H
authors.lastname: Guo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001777:Blood Coagulation / Q000187:drug effects*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects; D013923:Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone